Janux Therapeutics Inc. (JANX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to a loss of $0.55 per share a year ago.
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Janux Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 82 | $1,140 | $1,449.76 | $309.76 | 27.17% |
| NA Nizar Araji National Bank Of Canada /FI/ | 77 | $1,070.3 | $1,220.45 | $150.15 | 14.03% |
| BG Bart Gancher Intech Investment Management LLC | 11,473 | $296,904.12 | $181,847.05 | -$115,057.07 | -38.75% |
 Point72 Asset Management LP Point72 Asset Management LP | 1.99M | $36.43M | $32.14M | -$4.29M | -11.77% |
 Didric Cederholm Lion Point Capital LP | 19,000 | $262,200 | $380,000 | $117,800 | 44.93% |
Janux Therapeutics Inc. (JANX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Janux Therapeutics Inc. ever had a stock split?
Janux Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | David Alan Campbell CEO | NASDAQ (NMS) Exchange | 47103J105 CUSIP |
| US Country | 113 Employees | - Last Dividend | - Last Split | 11 Jun 2021 IPO Date |
Overview
Janux Therapeutics, Inc. is a pioneering biopharmaceutical company engaged in the innovative field of developing advanced immunotherapies aimed at treating cancer. At the forefront of technology with its Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms, Janux Therapeutics is dedicated to advancing the fight against cancer. Established in 2017 and operating from its headquarters in San Diego, California, the company is at the clinical stage, demonstrating its commitment to translating scientific discoveries into meaningful therapeutic options for patients. A key aspect of its strategy involves strategic collaborations, notably with Merck Sharp & Dohme Corp., to enhance the development and potential commercialization of its innovative TRACTr product candidates.
Products and Services
- JANX007
JANX007 represents Janux Therapeutics' advanced clinical candidate, specifically designed as a prostate-specific membrane antigen (PSMA-TRACTr). This cutting-edge therapy is currently being evaluated in a Phase 1 clinical trial targeting adults with metastatic castration-resistant prostate cancer (mCRPC) and is also being explored for its potential in combating the vasculature of other tumor types. JANX007 exemplifies the company's focus on addressing highly aggressive cancers and showcases its innovative approach to targeted immunotherapy.
- JANX008
Another key clinical candidate from Janux Therapeutics is JANX008, leveraging the epidermal growth factor receptor (EGFR-TRACTr) for therapeutic application. This candidate is in the midst of a Phase 1 clinical trial aimed at treating multiple solid cancers, including but not limited to colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. The versatility and breadth of JANX008's potential applications underscore Janux Therapeutics' dedication to combatting a wide range of challenging cancer types through innovative therapy options.
In addition to these clinical-stage developments, Janux Therapeutics maintains a robust pipeline of discovery stage products, reflecting its commitment to ongoing innovation and the pursuit of new therapeutic avenues for cancer treatment.
